Ellagic Acid
15 benefits mapped to clinical evidence across supplements.
Dose per serving from products
33 products in our catalogue print how much Ellagic Acid a serving holds.
Most common: 25 mg to 50 mg, 30% of 33 products.
| Dose per serving | Products |
|---|---|
| 5 mg or less | 2 |
| 5 mg to 10 mg | 6 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 10 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 6 |
| 250 mg to 500 mg | 4 |
Dose per serving from research
13 study groups in 11 studies say how much Ellagic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 mg to 250 mg, 69% of 13 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 3 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 9 |
Benefit Evidence
Research sources
Metabolism (6)
- Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes
PubMed ID: 32909365
T2D randomized double‑blind trial (180 mg/day EA) showed significant glucose and HOMA‑IR improvements — direct metabolic evidence.
- Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome
PubMed ID: 34330312
PCOS RCT (200 mg/day EA) improved HOMA‑IR and LDL and reduced AMH — robust metabolic/hormonal improvements.
- The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
PubMed ID: 40877731
MASLD RCT showed reduced liver fat and ALT—beneficial metabolic hepatic changes (but was combined with calorie restriction).
- A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
PubMed ID: 39885430
NAFLD RCT produced clinically significant improvements in triglycerides, LDL and ALT over 8 weeks.
- Clinical and Biological Efficacy of Thai Herbal Blood Lipid-Lowering Formulation for Borderline Hyperlipidemia: A Double-Blind Multicenter Randomized Controlled Trial
PubMed ID: 41144257
Multi‑herb product reduced LDL/total cholesterol and triglycerides in borderline hyperlipidemia (EA‑containing plants among constituents).
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
12‑week EA in overweight men improved multiple metabolic markers (TC, TG, HDL, LDL) in a randomized trial.
Inflammation (6)
- Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes
PubMed ID: 32909365
T2D trial explicitly reported significant CRP reduction and lower inflammatory status with ellagic acid.
- A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
PubMed ID: 39885430
NAFLD RCT decreased oxidative/inflammatory markers alongside clinical improvements.
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
MS trial showed marked decreases in IFN‑γ, NO, cortisol and inflammatory markers with improved clinical depression scores.
- Improving Effect of Ellagic Acid on Sleep Quality and Gastrointestinal Symptoms in Patient With Irritable Bowel Syndrome: Randomized Double-Blind Clinical Trial
PubMed ID: 34872895
IBS RCT reduced symptom severity and improved sleep; symptomatic improvements often reflect lowered gut inflammation.
- Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome
PubMed ID: 34330312
PCOS RCT produced improvements in HOMA‑IR and LDL and reduced AMH, indicating lowered inflammatory/metabolic stress.
- Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial
PubMed ID: 32839797
Pomegranate peel extract ± vitamin E significantly reduced CRP and IL‑6 in hemodialysis patients.
Skin health (6)
- Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone
PubMed ID: 23377328
Topical product containing EA + salicylic acid performed comparably to 4% hydroquinone for spot reduction (double‑blind trial).
- A method for maintaining the clinical results of 4% hydroquinone and 0.025% tretinoin with a cosmeceutical formulation
PubMed ID: 25844613
EA‑containing OTC formulation maintained and improved skin lightening over 20 weeks as a maintenance therapy.
- Phenolic-rich Pomegranate Peel Extract: In Vitro, Cellular, and In Vivo Activities for Skin Hyperpigmentation Treatment
PubMed ID: 32428937
Direct split‑face RCT of pomegranate peel extract (contains EA) showed improved facial skin lightening and safety.
- Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin
PubMed ID: 17190110
Oral pomegranate/EA reduced slight UV‑induced skin darkening over 4 weeks in a randomized, double‑blind human trial.
- Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study
PubMed ID: 18837701
Topical EA formulations reduced pigmentation comparably to arbutin in a small open study.
- Dyspigmentation, skin physiology, and a novel approach to skin lightening
PubMed ID: 24305422
Cosmeceutical with EA produced skin‑lightening results comparable to prescription therapy with better tolerability (investigator‑blinded trial).
Antioxidant (4)
- Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes
PubMed ID: 32909365
T2D RCT lowered CRP and inflammation consistent with antioxidant activity.
- Acute reduction of serum 8-iso-PGF2-alpha and advanced oxidation protein products in vivo by a polyphenol-rich beverage; a pilot clinical study with phytochemical and in vitro antioxidant characterization
PubMed ID: 21676230
Acute human pilot (polyphenol beverage including EA) showed large rapid reductions in oxidative stress markers and increased antioxidant capacity.
- A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
PubMed ID: 39885430
NAFLD RCT reported reductions in oxidative/inflammatory markers alongside lipid and ALT improvements.
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
MS trial showed reduced inflammatory markers and increased BDNF — consistent with antioxidant/anti‑oxidative stress effects.
Blood circulation (3)
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
12‑week EA in overweight men improved lipids (beneficial for vascular health) and related systemic markers.
- Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial
PubMed ID: 32839797
Hemodialysis RCT showed reductions in ICAM‑1 and inflammatory markers tied to endothelial health (PPE±vitE).
- Synergistic Effects of Sanghuang⁻Danshen Bioactives on Arterial Stiffness in a Randomized Clinical Trial of Healthy Smokers: An Integrative Approach to in silico Network Analysis
PubMed ID: 30621047
Randomized trial (Sanghuang–Danshen product containing EA among other bioactives) produced large reductions in arterial stiffness and lowered systolic BP with increased eNOS phosphorylation.
Hormone balance (3)
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
12‑week EA lowered salivary cortisol by ~22.7% in overweight men—evidence of HPA‑axis/hormonal modulation.
- Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome
PubMed ID: 34330312
PCOS RCT directly lowered AMH and improved insulin resistance and lipids — direct hormonal/ovarian marker effect.
- Polyphenol-Related Gut Metabotype Signatures Linked to Quality of Life in Postmenopausal Women: A Randomized, Placebo-Controlled Crossover Trial
PubMed ID: 41305622
Polyphenol mixture improved menopause‑related health domain and hot‑flash severity in metabotype responders (hormone‑related symptoms).
Wellbeing (3)
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
12‑week EA in overweight men improved lipids, increased BDNF, lowered cortisol and improved cognition—multidomain wellness effects.
- Improving Effect of Ellagic Acid on Sleep Quality and Gastrointestinal Symptoms in Patient With Irritable Bowel Syndrome: Randomized Double-Blind Clinical Trial
PubMed ID: 34872895
IBS trial reported improved sleep quality and symptom scores, improving overall well‑being.
- Polyphenol-Related Gut Metabotype Signatures Linked to Quality of Life in Postmenopausal Women: A Randomized, Placebo-Controlled Crossover Trial
PubMed ID: 41305622
Crossover trial of a polyphenol mixture including ellagic extracts produced modest but statistically significant QoL improvements.
Heart health (3)
- Synergistic Effects of Sanghuang⁻Danshen Bioactives on Arterial Stiffness in a Randomized Clinical Trial of Healthy Smokers: An Integrative Approach to in silico Network Analysis
PubMed ID: 30621047
Product containing EA improved arterial stiffness and lowered systolic BP in smokers—relevant to heart health.
- A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
PubMed ID: 39885430
NAFLD RCT lowered triglycerides and LDL—lipid improvements relevant to cardiovascular risk.
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
EA trial in overweight men improved lipid profile (HDL increase, LDL decrease), beneficial for heart wellness.
Immune support (3)
- Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes
PubMed ID: 32909365
T2D study reduced CRP, consistent with a measurable effect on systemic inflammation/immune activation.
- Effects of pomegranate peel extract and vitamin E on the inflammatory status and endothelial function in hemodialysis patients: a randomized controlled clinical trial
PubMed ID: 32839797
Hemodialysis RCT with pomegranate peel extract reduced CRP and IL‑6, indicating immunomodulatory effects.
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
MS trial lowered IFN‑γ and other inflammatory markers, demonstrating immune‑modulating effects.
Brain health (2)
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
Direct neurological endpoints: reduced depression, increased BDNF and serotonin in MS patients — strong brain‑relevant signals.
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
Large RCT in overweight men showed increased BDNF and cognitive improvements after 12 weeks of EA supplementation.
Mental clarity (2)
- Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
PubMed ID: 29053933
12‑week EA increased plasma BDNF and improved cognition in overweight middle‑aged men (randomized trial).
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
Strong triple‑blind RCT showed decreased depressive symptoms and increased BDNF/serotonin — consistent with improved mental clarity/mood.
Digestive support (2)
- Assessing the therapeutic use of Lafoensia pacari St. Hil. extract (mangava-brava) in the eradication of Helicobacter pylori: double-blind randomized clinical trial
PubMed ID: 16684267
Ellagic‑acid–rich plant extract did not eradicate H. pylori but about doubled symptom relief vs placebo (RCT—symptom benefit).
- Improving Effect of Ellagic Acid on Sleep Quality and Gastrointestinal Symptoms in Patient With Irritable Bowel Syndrome: Randomized Double-Blind Clinical Trial
PubMed ID: 34872895
Direct RCT in IBS patients showing significantly improved IBS severity and GI symptoms with ellagic acid.
Liver support (2)
- The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
PubMed ID: 40877731
Randomized double‑blind 200 mg/day EA for 8 weeks (with calorie restriction) in MASLD patients produced clinically relevant reductions in liver fat, stiffness and ALT.
- A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
PubMed ID: 39885430
180 mg/day EA for 8 weeks in NAFLD improved triglycerides, LDL, ALT and reduced oxidative/inflammatory markers (direct liver enzyme/lipid benefit).
Cell health (2)
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
Increased BDNF and reduced inflammatory/oxidative markers in MS patients suggest neuro‑cellular protective effects.
- Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients
PubMed ID: 24532260
Human colon tissue contained free EA, conjugates and urolithins after pomegranate extract—demonstrates tissue exposure to EA derivatives relevant to cellular protection.
Vitality (1)
- The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
PubMed ID: 37806153
Reduction in depressive symptoms and increases in serotonin/BDNF suggest improved energy/vitality.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Ellagic Acid
Search all40 products whose verified label declares Ellagic Acid — not every bottle that mentions it in a title.